Celldex Therapeutics prices $200.5M public offering of 7.425M shares at $27.00

Celldex Therapeutics, Inc.

Offering of 7,425,000 shares at $27.00 per share; underwriters have 30-day option for 1,113,750 additional shares.
Net proceeds expected ~$188.3M after discounts and expenses.
Proceeds to fund clinical/preclinical development including barzolvolimab and bispecific antibody platform.
Offering expected to close on or about Nov 10, 2023; Jefferies and Leerink Partners lead the underwriting.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Celldex Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (effective 2023-11-07).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters
Effective: 2023-11-07

Exact text from the filing

On November 7, 2023, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 7,425,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $27.00 per share (the “Offering”).

View on SEC.gov

Browse all material agreements →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.